Tirzepatida
GIP/GLP-1 co-agonist (dual incretin)
Shop
Every compound links to its technical sheet, with its mechanism, its level of evidence and its considerations stated without ambiguity. Purity, net content and batch are published as soon as the corresponding certificate of analysis is in.
Product intended for research use only. Not approved for human or veterinary use.
GIP/GLP-1 co-agonist (dual incretin)
GIP/GLP-1/glucagon triple agonist
Stabilized GHRH analogue
Copper tripeptide (glycyl-histidyl-lysine copper complex)
Dinucleotide coenzyme — not a peptide
Combined vial: BPC-157 5 mg / TB-500 5 mg
Combined vial: GHRH analogue and GH secretagogue
Combined vial: BPC-157 10 mg / GHK-Cu 50 mg / TB-500 10 mg
GLP-1 receptor agonist
Long-acting amylin analogue
Pentadecapeptide (sequence derived from a gastric protein)
Synthetic fragment related to thymosin β4
Selective GH secretagogue (ghrelin receptor / GHS-R agonist)
Long-acting GHRH analogue
GHRH analogue (fragment 1-29)
Melanocortin receptor agonist (MC4R)
Synthetic α-MSH analogue (non-selective melanocortin agonist)
Heptapeptide derived from ACTH (4-10)
Tetrapeptide (Ala-Glu-Asp-Gly)
Support material for reconstitution. These are not peptides and do not carry a compound technical sheet.
Diluyente con alcohol bencílico al 0.9 %
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.